Researchers resolve old mystery of how phages disarm pathogenic bacteria phys.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phys.org Daily Mail and Mail on Sunday newspapers.
A&M AgriLife researchers taking a stand against bacterial infection
The national institute of allergy and infectious diseases is supporting researchers at Texas A&M in their fight against bacterial infections.
and last updated 2021-04-29 16:42:03-04
COLLEGE STATION, TX â The national institute of allergy and infectious diseases is supporting researchers at Texas A&M in their fight against bacterial infections.
Niaid awarded the school s AgriLife research nearly $400,000 in grants for their findings on bacteriophage therapy, which researchers think, could yield novel ways to fight antimicrobial-resistant bacteria.
The grant, which provides two years of funding, will be used to address key knowledge gaps in the development of phages as preventive and therapeutic tools for bacterial infections.
Texas A&M AgriLife receives grant to support research on bacteriophage therapy
The National Institute of Allergy and Infectious Diseases, NIAID, part of the National Institutes of Health, NIH, has awarded $2.5 million in grants to support research on bacteriophage therapy, and Texas A&M AgriLife Research is among the grant recipients.
Woman, Dr. Lanying Zeng, sitting in a chair at a desk in her laboratory where she is conducting a study with phages.
Lanying Zeng, Ph.D., is one of the principal investigators for the new NIH-funded phages study focusing on pili suppression. (Texas A&M AgriLife photo by Laura McKenzie) Bacteriophage therapy is an emerging field that many researchers think could yield novel ways to fight antimicrobial-resistant bacteria. A Centers for Disease Control and Prevention report from 2019 showed antibiotic-resistant pathogens cause more than 2.8 million infections and more than 35,000 deaths annually in the U.S.
E-Mail
The National Institute of Allergy and Infectious Diseases, NIAID, part of the National Institutes of Health, NIH, has awarded $2.5 million in grants to support research on bacteriophage therapy, and Texas A&M AgriLife Research is among the grant recipients.
Woman, Dr. Lanying Zeng, sitting in a chair at a desk in her laboratory where she is conducting a study with phages.
Lanying Zeng, Ph.D., is one of the principal investigators for the new NIH-funded phages study focusing on pili suppression. (Texas A&M AgriLife photo by Laura McKenzie)
Bacteriophage therapy is an emerging field that many researchers think could yield novel ways to fight antimicrobial-resistant bacteria. A Centers for Disease Control and Prevention report from 2019 showed antibiotic-resistant pathogens cause more than 2.8 million infections and more than 35,000 deaths annually in the U.S.
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded $2.5 million in grants to 12 institutes around the world to support research on bacteriophage therapy. These awards represent NIAID’s first series of grants focused exclusively on research on this therapy, an emerging field that could yield new ways to fight antimicrobial-resistant bacteria. A 2019 report from CDC found that antibiotic-resistant pathogens cause more than 2.8 million infections in the U.S. each year and more than 35,000 people die.
A computer-generated rendition of a bacteriophage.
Image/NIAID
Bacteriophages (or “phages”) are viruses that can kill or incapacitate specific kinds of bacteria while leaving other bacteria and human cells unharmed. By gathering naturally-occurring phages, or by modifying or engineering phages to display certain properties, researchers hope to create novel anti-bacterial therapeutics. Because phages eliminate ba